SWOG clinical trial number
CTSU/B-33
A Randomized, Placebo-controlled, Double-blind Trial Evaluating the Effect of Exemestane in Clinical cT1-3NO-1MO Postmenopausal Breast Cancer Patients Completing at Least Five Years of Tamoxifen Therapy
Closed
Published
Abbreviated Title
ADVANCED
Activated
11/01/2002
Closed
02/18/2004
Participants
CTSU
Research committees
Breast Cancer
Treatment
Tamoxifen
Eligibility Criteria Expand/Collapse
The Southwest Oncology Group participated in this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.
Please contact the CTSU directly by either phone (1-888-823-5923) or on the CTSU website (http://www.ctsu.org/) for information.
Please contact the CTSU directly by either phone (1-888-823-5923) or on the CTSU website (http://www.ctsu.org/) for information.
Publication Information Expand/Collapse
2008
Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 Trial [PMID18332472]
Other Clinical Trials
SWOG Clinical Trial Number
CTSU-A012301
LoTam: A Randomized, Phase III Clinical Trial of Low-Dose Tamoxifen for Selected Patients with Molecular Low-Risk Early-Stage Breast Cancer
Research Committee(s)
Breast Cancer
Activated
02/05/2025
Open
Phase
SWOG Clinical Trial Number
S2206
A Randomized trial of neoadjuvant durvalumab plus chemotherapy versus chemotherapy alone for Adults with MammaPrint Ultrahigh (MP2) hormone receptor (HR) positive /Human Epidermal Growth Factor receptor (HER2) negative stage II-III breast cancer
Research Committee(s)
Breast Cancer
Symptom Control and Quality of Life
Activated
10/30/2023
Accrual
29%
Open
Phase
SWOG Clinical Trial Number
S2212
TIL Adapted Neo adjuvant Chemotherapy Optimization in Triple negative breast cancer (SCARLET)
Research Committee(s)
Breast Cancer
Activated
07/21/2023
Accrual
43%
Open
Phase